LYG
MCID: LYM051
MIFTS: 47

Lymphomatoid Granulomatosis (LYG) malady

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Lymphomatoid Granulomatosis

Aliases & Descriptions for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 38 50 56 52 69
Lyg 56

Characteristics:

Orphanet epidemiological data:

56
lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA86869
ICD10 via Orphanet 34 C83.8
MESH via Orphanet 43 D008230
UMLS via Orphanet 70 C0024307

Summaries for Lymphomatoid Granulomatosis

NIH Rare Diseases : 50 lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as b lymphocytes. these b cells can build up in the tissues of the body, causing damage to the blood vessels. in many cases of lymphomatoid granulomatosis, the abnormal b cells contain the epstein-barr virus. the disease is more common in men, usually after the fifth decade of life. lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. rarely, the disorder can affect the kidneys or liver. the cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab. occasionally, the disorder resolves on its own without treatment. there has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a b-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a b-cell lymphoma. the prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases.  last updated: 1/4/2017

MalaCards based summary : Lymphomatoid Granulomatosis, also known as lyg, is related to lymphoproliferative syndrome 1 and lymphoproliferative syndrome, x-linked, 1, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Allograft rejection. The drugs Ciprofloxacin and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and b cells.

Wikipedia : 71 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 lymphoproliferative syndrome 1 11.2
2 lymphoproliferative syndrome, x-linked, 1 11.1
3 lymphoma 10.4
4 cerebritis 10.2
5 arthritis 10.1
6 rheumatoid arthritis 10.1
7 alström syndrome 10.1 GZMB TIA1
8 skeletal muscle cancer 10.1 GZMB TIA1
9 tibial adamantinoma 10.1 GZMB TIA1
10 superior limbic keratoconjunctivitis 10.1 GZMB TIA1
11 collagen type iii glomerulopathy 10.1 GZMB TIA1
12 leukemia 10.1
13 acquired immunodeficiency syndrome 10.1
14 fibrosclerosis of breast 10.1 GZMB TIA1
15 uterine ligament endometrioid adenocarcinoma 10.1 GZMB TIA1
16 congenital sucrase-isomaltase deficiency with starch and lactose intolerance 10.1 GZMB TIA1
17 linear lichen planus 10.1 GZMB TIA1
18 macrogyria, pseudobulbar palsy and mental retardation 10.0 GZMB TIA1
19 malignant teratoma 10.0 GZMB TIA1
20 cerebral lipidosis 10.0 GZMB TIA1
21 post-transplant lymphoproliferative disease 10.0 GZMB TIA1
22 childhood immature teratoma of ovary 10.0 GZMB TIA1
23 plasmodium ovale malaria 10.0 GZMB TIA1
24 mixed cell type cancer 10.0 GZMB TIA1
25 ceruminoma 10.0 IFNA1 IFNA2
26 lip cancer 10.0 GZMB TIA1
27 mast-cell leukemia 10.0 CXCL9 GZMB
28 hyperaldosteronism, familial, type ii 10.0 GZMB TIA1
29 chondrodysplasia punctata, tibia-metacarpal type 10.0 IFNA1 IFNA2
30 aortic arch interruption 10.0 GZMB TIA1
31 circumscribed cutaneous aplasia of the vertex 10.0 IFNA1 IFNA2
32 congenital disorder of glycosylation, type iq 10.0 IFNA1 IFNA2
33 b-cell lymphomas 10.0
34 polymorphic reticulosis 10.0
35 pneumonia 10.0
36 vasculitis 10.0
37 anterior foramen magnum meningioma 9.9 IFNA1 IFNA2
38 noninfectious dermatoses of eyelid 9.9 IFNA1 IFNA2
39 lethal midline granuloma 9.9
40 hematopoietic stem cell transplantation 9.9
41 neuropathy 9.9
42 senile cataract 9.9 IFNA1 IFNA2
43 erythrocytosis, somatic 9.9 IFNA1 IFNA2
44 hemoglobinopathy 9.9 IFNA1 IFNA2
45 exophthalmos 9.9 IFNA1 IFNA2
46 saethre-chotzen syndrome 9.8 IFNA1 IFNA2
47 cervicitis 9.8
48 mediastinitis 9.8
49 lung disease 9.8
50 lymphoblastic leukemia 9.8

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:



Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:


fever, malaise

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
4
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
8
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
9 Clavulanic Acid Phase 3
10 Analgesics Phase 3,Phase 1,Phase 2
11 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
12 Amoxicillin-Potassium Clavulanate Combination Phase 3
13 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
14 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
15 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1
16 Anesthetics Phase 3
17 Anesthetics, Dissociative Phase 3
18 Anesthetics, General Phase 3
19 Anesthetics, Intravenous Phase 3
20 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 beta-Lactamase Inhibitors Phase 3
23 Excitatory Amino Acid Antagonists Phase 3
24 Excitatory Amino Acids Phase 3
25 Anti-Infective Agents Phase 3,Phase 1,Phase 2
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Antitubercular Agents Phase 3
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
29 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
30 ferric gluconate Phase 3
31 pancreatic polypeptide Phase 3
32 Adjuvants, Anesthesia Phase 3
33 Narcotics Phase 3
34 Hematinics Phase 3,Phase 2
35 Analgesics, Opioid Phase 3
36 Ferric Compounds Phase 3
37 Liver Extracts Phase 3,Phase 1,Phase 2
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39 Cola Nutraceutical Phase 3,Phase 1,Phase 2
40 Orange Nutraceutical Phase 3
41 Glutamic Acid Nutraceutical Phase 3
42 Iron Supplement Nutraceutical Phase 3
43
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
44
Cyclosporine Approved, Investigational, Vet_approved Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
45
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
46
Etoposide Approved Phase 1, Phase 2, Early Phase 1 33419-42-0 36462
47
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
48
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
49
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
50
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 180)
id Name Status NCT ID Phase
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
9 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
10 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
11 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
12 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2
13 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Unknown status NCT02134262 Phase 1, Phase 2
14 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2
15 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
16 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
17 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
18 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2
19 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2
20 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
21 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
22 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2
23 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2
24 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
25 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2
26 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
27 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2
28 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
29 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
30 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
31 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
32 Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Completed NCT00005040 Phase 2
33 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2
34 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2
35 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2
36 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00238433 Phase 2
37 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2
38 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2
39 Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00098566 Phase 2
40 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases Completed NCT00453206 Phase 2
41 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2
42 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
43 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2
44 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2
45 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2
46 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2
47 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2
48 Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT00612716 Phase 2
49 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2
50 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

39
Lung, Skin, B Cells, Liver, Kidney, Brain, T Cells

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 399)
id Title Authors Year
1
Lymphomatoid Granulomatosis: Two Different Phenotypes of Computed Tomography Findings. ( 27768635 )
2016
2
Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. ( 27521314 )
2016
3
Lymphomatoid granulomatosis of the brain: A case report. ( 27656321 )
2016
4
Lymphomatoid granulomatosis initially presenting as ulcerated subcutaneous and muscle lesions without pulmonary involvement. ( 27988929 )
2016
5
Lymphomatoid Granulomatosis with Paraneoplastic Polymyositis: A Rare Malignancy with Rare Complication. ( 26966605 )
2016
6
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. ( 27454071 )
2016
7
Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. ( 27671987 )
2016
8
Pulmonary Lymphomatoid Granulomatosis- a Case Report with Review of Literature. ( 27872542 )
2016
9
Lymphomatoid granulomatosis coronary vasculitis and cardiomyopathy: Depiction of extent and severity on cardiac CT. ( 27021253 )
2016
10
Lymphomatoid granulomatosis - A rare pulmonary lymphoproliferative disease. ( 26898887 )
2016
11
Lymphomatoid Granulomatosis with Central Nervous System Involvement Successfully Treated with Cyclophosphamide, High-dose Cytarabine, Dexamethasone, Etoposide, and Rituximab (CHASER therapy) Followed by Brain Irradiation: A Case Study. ( 26096049 )
2015
12
Pulmonary lymphomatoid granulomatosis. A rare entity in the differential diagnosis of pulmonary nodules. ( 26078192 )
2015
13
Pulmonary manifestation of lymphomatoid granulomatosis. ( 26071366 )
2015
14
Low grade pulmonary lymphomatoid granulomatosis with an endobronchial mass. ( 25861350 )
2015
15
Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy. ( 25758078 )
2015
16
Fever, Dry Cough and Exertional Dyspnea: Pulmonary Lymphomatoid Granulomatosis Masquerading as Pneumonia, Granulomatosis with Polyangiitis and Infectious Mononucleosis. ( 26631890 )
2015
17
Primary Orbital Lymphomatoid Granulomatosis in a 1-Year-Old Child. ( 26692728 )
2015
18
Lymphomatoid Granulomatosis. ( 26386275 )
2015
19
Lymphomatoid granulomatosis mimicking vasculitis. ( 26382276 )
2015
20
Clinical, imaging and histopathological features of isolated CNS lymphomatoid granulomatosis. ( 25709167 )
2015
21
Granulomatous Lymphoproliferative Disorders: Granulomatous Slack Skin and Lymphomatoid Granulomatosis. ( 26143428 )
2015
22
A case of lymphomatoid granulomatosis presenting with cutaneous lesions. ( 27051739 )
2015
23
Paediatric grade-II lymphomatoid granulomatosis: (18)F-FDG PET/CT monitoring of disease activity. ( 26522001 )
2015
24
Epstein-Barr virus-driven B Cell Proliferation with CD4(+) T Cell Expansion: A Lymphomatoid Granulomatosis-like Disease Related to Hyperinterleukin-10 Secretion of Remarkably Favourable Outcome with Rituximab. ( 26332210 )
2015
25
Biopsy-proven muscular involvement of lymphomatoid granulomatosis assessed by (18)FDG-PET Scan. ( 25623523 )
2015
26
Pathology in Practice. Lymphomatoid granulomatosis of lung tissue and mediastinal lymph node in a dog. ( 26517613 )
2015
27
Fatal necrotizing angiotropic Epstein-Barr virus-negative large B-cell lymphoma: a case report with unusual clinicopathological features in-between lymphomatoid granulomatosis and T-cell/histiocyte-rich large B-cell lymphoma. ( 25546693 )
2014
28
Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis. ( 25674479 )
2014
29
Childhood Lymphomatoid Granulomatosis: A Report of 2 Cases and Review of the Literature. ( 24390446 )
2014
30
Lymphomatoid Granulomatosis-A Single Institute Experience: Pathologic Findings and Clinical Correlations. ( 25321327 )
2014
31
Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. ( 25022612 )
2014
32
Another rare finding of lymphomatoid granulomatosis on CT scan. ( 24798854 )
2014
33
Pulmonary lymphomatoid granulomatosis in a 4-year-old girl. ( 25432443 )
2014
34
[Methotrexate-related lymphomatoid granulomatosis successfully treated with discontinuation of methotrexate and radiotherapy to brain]. ( 24681935 )
2014
35
Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. ( 25130128 )
2014
36
Cutaneous lesions in a CLIPPERS patient: further confusion between CLIPPERS and grade I lymphomatoid granulomatosis. ( 24976067 )
2014
37
Oral lymphomatoid granulomatosis, the first sign of a 'rare disease': a case report. ( 24886196 )
2014
38
An eschar and violaceous nodules as the presenting signs of lymphomatoid granulomatosis. ( 25419752 )
2014
39
Pyrexia, Lung nodules, Granulomas: Pulmonary Lymphomatoid Granulomatosis. ( 25332635 )
2014
40
Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis. ( 23857444 )
2014
41
Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman. ( 25535225 )
2014
42
Orbital lymphomatoid granulomatosis - a rare cause of proptosis. ( 25381000 )
2014
43
Lymphomatoid granulomatosis of central nervous system and lung driven by epstein barr virus proliferation: successful treatment with rituximab-containing chemotherapy. ( 24678394 )
2014
44
EBV-Negative Cutaneous Lymphomatoid Granulomatosis With Concomitant EBV-Positive Pulmonary Involvement: A Potential Diagnostic and Prognostic Pitfall. ( 25148107 )
2014
45
Lymphomatoid granulomatosis involving the central nervous system: A case report and review of the literature. ( 24932245 )
2014
46
Lymphomatoid Granulomatosis Presenting with Cutaneous Involvement: A Case Report with Review of the Literature. ( 25355540 )
2014
47
Large granular lymphocyte leukemia and lymphomatoid granulomatosis in the same patient: fortuitous association? ( 22799270 )
2013
48
Lymphomatoid granulomatosis with CNS involvement can lead to spontaneous remission: case study. ( 23582284 )
2013
49
Reversible iatrogenic, MTX-associated EBV-driven lymphoproliferation with histopathological features of a lymphomatoid granulomatosis in a patient with rheumatoid arthritis. ( 23529185 )
2013
50
Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report. ( 23948061 )
2013

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.69 GZMB IFNA2 TIA1
2 cytokine-mediated signaling pathway GO:0019221 9.52 IFNA1 IFNA2
3 B cell differentiation GO:0030183 9.49 IFNA1 IFNA2
4 type I interferon signaling pathway GO:0060337 9.48 IFNA1 IFNA2
5 humoral immune response GO:0006959 9.46 IFNA1 IFNA2
6 B cell proliferation GO:0042100 9.43 IFNA1 IFNA2
7 response to exogenous dsRNA GO:0043330 9.4 IFNA1 IFNA2
8 regulation of type I interferon-mediated signaling pathway GO:0060338 9.37 IFNA1 IFNA2
9 T cell activation involved in immune response GO:0002286 9.32 IFNA1 IFNA2
10 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA1 IFNA2
11 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA1 IFNA2
12 defense response to virus GO:0051607 9.13 CXCL9 IFNA1 IFNA2
13 defense response GO:0006952 8.8 CXCL9 IFNA1 IFNA2

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cytokine activity GO:0005125 9.13 CXCL9 IFNA1 IFNA2
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2

Sources for Lymphomatoid Granulomatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....